The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

Michelle Tarver, of the FDA's Center for Devices and Radiological Health, said: "Today's clearance is an important step for ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

A first-of-its-kind blood test developed by Malvern-based Fujirebio Diagnostics to help diagnose Alzheimer’s disease has ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

Fujirebio recently announced that the US Food and Drug Administration (FDA) has granted clearance for the company’s Lumipulse in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in ...

The US Food and Drug Administration (FDA) has approved Fujirebio Diagnostics’ Alzheimer’s disease (AD) blood test to help ...

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the ...

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

The Food and Drug Administration has cleared the blood test to help diagnose Alzheimer's disease, potentially making it ...